Drugs / A/Arkansas/08/2020 (pH1N1)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07110532 | Sep 2025 → Oct 2026 expected | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A/Arkansas/08/2020 (pH1N1) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07110532 ↗ |
| Modality | Other / unclassified | “GMP-grade, cell-based influenza A (pH1N1) virus” NCT07110532 ↗ |
| Route | Intranasal | “single intranasal virus” NCT07110532 ↗ |